Artivion (NYSE:AORT – Get Free Report) had its target price decreased by stock analysts at Stifel Nicolaus from $33.00 to $30.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 17.92% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. JMP Securities reissued a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Needham & Company LLC lowered their price target on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Oppenheimer raised their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $31.40.
View Our Latest Analysis on Artivion
Artivion Price Performance
Artivion (NYSE:AORT – Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, research analysts expect that Artivion will post 0.37 EPS for the current fiscal year.
Insider Buying and Selling at Artivion
In other news, CFO Lance A. Berry sold 3,259 shares of Artivion stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $89,003.29. Following the transaction, the chief financial officer now owns 75,805 shares in the company, valued at approximately $2,070,234.55. The trade was a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the transaction, the vice president now owns 33,503 shares in the company, valued at approximately $1,005,090. This represents a 18.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 77,224 shares of company stock worth $2,162,330 over the last 90 days. Corporate insiders own 8.10% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Quarry LP grew its stake in shares of Artivion by 210.8% in the third quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the last quarter. R Squared Ltd bought a new stake in shares of Artivion in the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI bought a new stake in shares of Artivion in the fourth quarter worth about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Artivion in the fourth quarter worth about $64,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.
About Artivion
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
See Also
- Five stocks we like better than Artivion
- How to Capture the Benefits of Dividend Increases
- Buffett’s on the Sidelines – Should You Follow?
- What Are Dividends? Buy the Best Dividend Stocks
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- What is a Bond Market Holiday? How to Invest and Trade
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.